PH19203A - Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent - Google Patents

Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent

Info

Publication number
PH19203A
PH19203A PH28429A PH28429A PH19203A PH 19203 A PH19203 A PH 19203A PH 28429 A PH28429 A PH 28429A PH 28429 A PH28429 A PH 28429A PH 19203 A PH19203 A PH 19203A
Authority
PH
Philippines
Prior art keywords
monoacyloxy
diacyloxy
propoxymethyl
purines
substituted
Prior art date
Application number
PH28429A
Other languages
English (en)
Inventor
Julien P H Verheyden
John C Martin
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of PH19203A publication Critical patent/PH19203A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1786—Unsaturated ethers containing hydroxy or O-metal groups containing halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PH28429A 1982-02-01 1983-01-27 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent PH19203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34470382A 1982-02-01 1982-02-01
US07/451,262 US5250535A (en) 1982-02-01 1982-12-22 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent

Publications (1)

Publication Number Publication Date
PH19203A true PH19203A (en) 1986-01-31

Family

ID=26994067

Family Applications (5)

Application Number Title Priority Date Filing Date
PH28429A PH19203A (en) 1982-02-01 1983-01-27 Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines as antiviral agent
PH30840A PH20360A (en) 1982-02-01 1984-06-19 A process for preparing substituted 9-(1- or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines
PH30841A PH22817A (en) 1982-02-01 1984-06-19 Process for preparing substituted 9-(1-or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines
PH30839A PH20099A (en) 1982-02-01 1984-06-19 Process for preparation of substituted 9-(1-or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines using carboxylic acid anhydrides or dicyclohexylcarbodiimide
PH32259A PH22824A (en) 1982-02-01 1985-05-13 Process of preparing 9-(1- or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines

Family Applications After (4)

Application Number Title Priority Date Filing Date
PH30840A PH20360A (en) 1982-02-01 1984-06-19 A process for preparing substituted 9-(1- or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines
PH30841A PH22817A (en) 1982-02-01 1984-06-19 Process for preparing substituted 9-(1-or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines
PH30839A PH20099A (en) 1982-02-01 1984-06-19 Process for preparation of substituted 9-(1-or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines using carboxylic acid anhydrides or dicyclohexylcarbodiimide
PH32259A PH22824A (en) 1982-02-01 1985-05-13 Process of preparing 9-(1- or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl)purines

Country Status (20)

Country Link
US (1) US5250535A (no)
EP (1) EP0085424A3 (no)
KR (1) KR890000191B1 (no)
AU (2) AU572777B2 (no)
BR (1) BR8300475A (no)
DD (1) DD206781A5 (no)
DK (1) DK29183A (no)
ES (1) ES519423A0 (no)
FI (1) FI79851C (no)
GR (1) GR81321B (no)
HU (1) HU193874B (no)
IL (1) IL67791A0 (no)
IN (1) IN157856B (no)
NO (1) NO161372C (no)
NZ (1) NZ203128A (no)
PH (5) PH19203A (no)
PL (1) PL140556B1 (no)
PT (1) PT76149B (no)
RO (3) RO86234B (no)
ZW (1) ZW2583A1 (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS594082A2 (en) * 1981-08-11 1989-08-14 Wellcome Found Method of antiviral effective 2-amino-9-/(2-hydroxy-1-hydroxymethyl-ethoxy)methyl/purines production
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
ZW22283A1 (en) * 1982-10-14 1985-05-22 Wellcome Found Antiviral compounds
US4609662A (en) * 1982-10-14 1986-09-02 Burroughs Wellcome Co. Method for using purine derivatives
US4544634A (en) * 1982-10-14 1985-10-01 Burroughs Wellcome Co. Method of producing acyclovir
US4880820A (en) * 1983-06-24 1989-11-14 Merck & Co., Inc. Guanine derivatives
US4897479A (en) * 1983-09-30 1990-01-30 Merck & Co., Inc. Arylsulfonyloxy purine intermediates
EP0138683A3 (en) * 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
IL73682A (en) * 1983-12-20 1991-08-16 Medivir Ab Antiviral pharmaceutical compositions containing 9-hydroxy aliphatic derivatives of guanine,some new such derivatives and process for their preparation
EP0152316B1 (en) * 1984-01-26 1989-07-26 Merck & Co. Inc. Substituted butyl guanines and their utilization in antiviral compositions
US4579849A (en) * 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
WO1986000901A1 (en) * 1984-07-20 1986-02-13 Gauntt Charles O Immunoregulatory and anti-viral compound
KR910000198B1 (ko) * 1984-12-12 1991-01-23 신텍스(유.에스.에이.) 인코포레이티드 글리세롤의 알콕시메틸 에테르 및 알콕시메틸 에스테르의 제조방법
DK224286A (da) * 1985-05-15 1986-11-16 Wellcome Found 2',3'-dideoxy-nucleosider
DE3627024A1 (de) * 1985-09-24 1987-04-02 Hoechst Ag In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
US4966895A (en) * 1989-02-02 1990-10-30 Merck & Co. Inc. Cyclic monophosphates of purine and pyrimidine acyclonucleosides as anti-retroviral agents
IE980216A1 (en) * 1989-04-17 2000-02-23 Scotia Holdings Plc Anti-virals
GB2260319B (en) 1991-10-07 1995-12-06 Norsk Hydro As Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
US5670506A (en) * 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5565565A (en) * 1994-08-04 1996-10-15 Syntex (U.S.A.) Inc. Preparation of N-9 substituted guanine compounds
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
GB0708258D0 (en) * 2007-04-27 2007-06-06 Katholleke Universiteit Leuven New anti-viral nulceoside analogs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4199574A (en) * 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
US4347360A (en) * 1980-09-16 1982-08-31 Ens Bio Logicals Inc. Ring open nucleoside analogues
US4355032B2 (en) * 1981-05-21 1990-10-30 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
CS594082A2 (en) * 1981-08-11 1989-08-14 Wellcome Found Method of antiviral effective 2-amino-9-/(2-hydroxy-1-hydroxymethyl-ethoxy)methyl/purines production
US4816447A (en) * 1981-08-26 1989-03-28 Merck & Co., Inc. Anti-viral guanine compounds
NZ201662A (en) * 1981-08-26 1986-07-11 Merck & Co Inc 9-(1,3-(and 2,3)-dihydroxy-1-(and 2)-propoxy-methyl)guanine derivatives and methods for their preparation

Also Published As

Publication number Publication date
PT76149A (en) 1983-02-01
NO161372C (no) 1989-08-09
PH20099A (en) 1986-09-24
IN157856B (no) 1986-07-12
PL140556B1 (en) 1987-05-30
ES8504194A1 (es) 1985-04-16
GR81321B (no) 1984-12-11
NO830316L (no) 1983-08-02
PH22817A (en) 1989-01-19
US5250535A (en) 1993-10-05
PT76149B (en) 1985-11-25
DK29183A (da) 1983-08-02
NZ203128A (en) 1987-08-31
FI79851B (fi) 1989-11-30
KR890000191B1 (ko) 1989-03-10
PL240367A1 (en) 1985-10-08
HU193874B (en) 1987-12-28
RO86234B (ro) 1985-03-31
RO86234A (ro) 1985-03-15
ZW2583A1 (en) 1983-05-11
EP0085424A3 (en) 1984-07-18
NO161372B (no) 1989-05-02
IL67791A0 (en) 1983-05-15
RO89142A (ro) 1986-04-30
AU1096183A (en) 1983-08-11
DK29183D0 (da) 1983-01-25
BR8300475A (pt) 1983-11-01
AU1261488A (en) 1988-06-02
FI830254A0 (fi) 1983-01-26
RO89143A (ro) 1986-04-30
EP0085424A2 (en) 1983-08-10
KR840003253A (ko) 1984-08-20
DD206781A5 (de) 1984-02-08
PH20360A (en) 1986-12-04
AU572777B2 (en) 1988-05-19
PH22824A (en) 1989-01-19
ES519423A0 (es) 1985-04-16
FI79851C (fi) 1990-03-12
FI830254L (fi) 1983-08-02

Similar Documents

Publication Publication Date Title
ZW2583A1 (en) Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
US4355032B2 (en) 9-(1,3-dihydroxy-2-propoxymethyl)guanine as antiviral agent
PH23593A (en) Difluoronucleosides as antiviral agents
EP0141927A3 (en) Antiviral guanine derivatives
GB2119650B (en) Antiviral isothiosemicarbazones
ZA851657B (en) Antiviral compounds
JPS5651423A (en) Antiviral agent
IL69417A0 (en) Imidazo(1,2-a)pyrimidines
AU564194B2 (en) 9 - substituted guanines as antiviral agents
ZA837814B (en) Antiviral agent
DE3468322D1 (en) Antiviral agent
ZA83626B (en) Substituted 9-(1 or 3-monoacyloxy or 1, 3-diacyloxy-2-propoxy-methyl purines as antiviral agent
GB2138418B (en) Novel s-triazole(1,5-a)pyrimidine derivatives
PH19080A (en) (1,2,4) triazolo (4,3-a) quinoxaline-4-amine derivatives
GB8306905D0 (en) Substituted 1h-pyrazolo(1,5-a)pyrimidines
IE822049L (en) Antiviral purines
GB8329344D0 (en) Bronchodilatory azepino(1,2-a)pyrimidine derivatives
PH17379A (en) 4-arylaliphatic-isoxazoles useful as antiviral agents
GB8728869D0 (en) Antiviral agent
ZA886461B (en) Antiviral agent
SG114493G (en) Antiviral guanine derivatives
IE820064L (en) 2-oxa-bicyclo(3,3,0)octanes
IE821160L (en) Antiviral composition
ZA8421B (en) Antiviral compounds
ZM7883A1 (en) Antiviral compounds